Advertisement

Clinical Rheumatology

, Volume 33, Issue 3, pp 415–418 | Cite as

Pneumocystis jirovecii pneumonia in two patients with systemic lupus erythematosus after rituximab therapy

  • F Bonilla-Abadía
  • J F Betancurt
  • J C Pineda
  • J D Vélez
  • G J Tobón
  • C A Cañas
Brief Report

Abstract

New cases of Pneumocystis jirovecii pneumonia (PJP) have recently been reported in patients with systemic lupus erythematosus (SLE) after rituximab therapy. Several factors may contribute to susceptibility to P. jirovecii infection in this type of patients, including the immunological characteristics of the disease, the mechanisms of rituximab action, environmental factors, and the biological characteristics of the fungus. We report two patients with SLE who developed PJP after rituximab therapy.

Keywords

Pneumonia Pneumocystis Pneumocystis jirovecii Rituximab Systemic Systemic lupus erythematosus 

Notes

Disclosures

None

References

  1. 1.
    Choi J, Kim ST, Craft J (2012) The pathogenesis of systemic lupus erythematosus an update. Curr Opin Immunol 24:651–657PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22:4711–4716PubMedCrossRefGoogle Scholar
  3. 3.
    Dass S, Vital EM, Emery P (2006) Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 7:2559–2570PubMedCrossRefGoogle Scholar
  4. 4.
    Bonilla-Abadía F, Echeverri AF, Izquierdo JH, Cañas F, Cañas CA (2012) Efficacy and safety of rituximab in the treatment of vasculitic leg ulcers associated with hepatitis C virus infection. Case report Rheumatol 2012:923897Google Scholar
  5. 5.
    Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltran-Castillo A, Jimenez-Hernandez M et al (2010) Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus 19:213–219PubMedCrossRefGoogle Scholar
  6. 6.
    Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA (2006) B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 176:6147–6154PubMedGoogle Scholar
  7. 7.
    Teichmann LL, Woenckhaus M, Vogel C, Salzberger B, Scholmerich J, Fleck M (2008) Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford) 47:1256–1257CrossRefGoogle Scholar
  8. 8.
    Hugle B, Solomon M, Harvey E, James A, Wadhwa A et al (2010) Pneumocystis jirovecii pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res (Hoboken) 62:1661–1664CrossRefGoogle Scholar
  9. 9.
    Tsai MJ, Chou CW, Lin FC, Chang SC (2012) Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus after rituximab therapy. Lupus 21:914–918PubMedCrossRefGoogle Scholar
  10. 10.
    Su GX, Wu FQ, Wang F, Zhou ZX, Huang XL, Lu J (2012) Rituximab therapy for severe pediatric systemic lupus erythematosus. Zhongha Er Ke Za 50:697–704Google Scholar
  11. 11.
    Gigliotti F, Wright TW (2005) Immunopathogenesis of Pneumocystis jirovecii pneumonia. Expert Rev Mol Med 7:1–16PubMedCrossRefGoogle Scholar
  12. 12.
    Ferreira S, Vasconcelos J, Marinho A, Farinha F, Almeida I et al (2009) CD4 lymphocytopenia in systemic lupus erythematosus. Acta Reumatol Port 34:200–206PubMedGoogle Scholar
  13. 13.
    Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S et al (2008) Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 3:1526–1533PubMedCrossRefGoogle Scholar
  14. 14.
    Gea-Banacloche JC (2010) Rituximab-associated infections. Semin Hematol 47:187–198PubMedCrossRefGoogle Scholar
  15. 15.
    Katsuya H, Suzumiya J, Sasaki H, Ishitsuka K, Shibata T et al (2009) Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 50:1818–1823PubMedCrossRefGoogle Scholar
  16. 16.
    Castagnola E, Dallorso S, Faraci M, Morreale G, Di Martino D et al (2003) Long-lasting hypogammaglobulinemia following rituximab administration for Epstein–Barr virus-related post-transplant lymphoproliferative disease preemptive therapy. J Hematother Stem Cell Res 12:9–10PubMedCrossRefGoogle Scholar
  17. 17.
    Masur H, Jones TC (1979) The interaction in vitro of Pneumocystis carinii with macrophages and L-cells. J Exp Med 147:157–170CrossRefGoogle Scholar
  18. 18.
    Chesnut RW, Grey HM (1982) Antigen presentation by B cells and its significance in TB interactions. Adv Immunol 39:51–94CrossRefGoogle Scholar
  19. 19.
    Marcotte H, Levesque D, Delanay K, Bourgeault A, de la Durantaye R et al (1996) Pneumocystis carinii infection in transgenic B cell-deficient mice. J Infect Dis 173:1034–1037PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2014

Authors and Affiliations

  • F Bonilla-Abadía
    • 1
  • J F Betancurt
    • 2
  • J C Pineda
    • 3
  • J D Vélez
    • 4
  • G J Tobón
    • 1
  • C A Cañas
    • 1
  1. 1.Rheumatology Unit, Cra. 98N. 18-49Fundación Valle del Lili-ICESI UniversityCaliColombia
  2. 2.Internal Medicine UnitFundación Valle del Lili-CES UniversityCaliColombia
  3. 3.Internal Medicine UnitFundación Valle del Lili-ICESI UniversityCaliColombia
  4. 4.Infectious Diseases UnitFundación Valle del LiliCaliColombia

Personalised recommendations